The SOLAR-1 trial is analyzing the efficacy of alpelisib on tumor harboring activating PIK3CA mutations and can already show a benefit for such patients, which led to the approval of alpelisib and the therascreen PIK3CA RGQ PCR kit by the FDA [39]. This evidence concerns the gene PIK3CA and neoplasm.